Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis.

被引：0
|
作者：
Pant, Shubham
Schuler, Martin H.
Iyer, Gopa
Witt, Olaf
Doi, Toshihiko
Qin, Shukui
Tabernero, Josep
Reardon, David A.
Massard, Christophe
Welsh, Liam
Lugowska, Iwona A.
Carranza, Omar
Stuyckens, Kim
Liao, Huimin
Najmi, Saltanat
Hammond, Constance
Thomas, Shibu
Triantos, Spyros
Sweiti, Hussein
Loriot, Yohann
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Hosp Essen, West German Canc Ctr, Essen, Germany
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Univ Heidelberg Hosp, Hopp Childrens Canc Ctr KiTZ, German Canc Res Ctr Heidelberg, Heidelberg, Germany
[5] Natl Ctr Tumor Dis NCT Heidelberg, Heidelberg, Germany
[6] Natl Canc Ctr Hosp East, Chiba, Japan
[7] Nanjing Univ Chinese Med, Jinling Hosp, Nanjing, Peoples R China
[8] Vall dHebron Univ Hosp, Barcelona, Spain
[9] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[10] Dana Farber Canc Inst, Boston, MA USA
[11] Univ Paris Saclay, Gustave Roussy, Villejuif, France
[12] Royal Marsden NHS Fdn Trust, London, England
[13] Narodowy Instytut Onkologii, Marii Sklodowskiej Curie Panstwowy Inst Badawczy, Warsaw, Poland
[14] Hosp Privado Comunidad Mar Plata, Mar Del Plata, Argentina
[15] Janssen Res & Dev, Beerse, PA, Belgium
[16] Janssen Res & Dev, Shanghai, Peoples R China
[17] Janssen Res & Dev, Spring House, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3121
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results
    Loriot, Yohann
    Schuler, Martin H.
    Iyer, Gopa
    Witt, Olaf
    Doi, Toshihiko
    Qin, Shukui
    Tabernero, Josep
    Reardon, David A.
    Massard, Christophe
    Palmer, Daniel
    Lugowska, Iwona
    Coward, Jermaine
    Corassa, Marcelo
    Stuyckens, Kim
    Liao, Huimin
    Najmi, Saltanat
    Hammond, Constance
    Santiago-Walker, Ademi E.
    Sweiti, Hussein
    Pant, Shubham
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Efficacy and safety of erdafitinib in pediatric patients with advanced solid tumors and FGFR alterations in the phase 2 RAGNAR trial
    Witt, Olaf
    Sait, Sameer Farouk
    Diez, Blanca D.
    Cardoso, Agustin
    Reardon, David A.
    Welsh, Liam
    Shih, Kent C.
    Baldini, Capucine
    Massard, Christophe
    Loriot, Yohann
    Pant, Shubham
    Sweiti, Hussein
    Thomas, Shibu
    Hammond, Constance
    Najmi, Saltanat
    Triantos, Spyros
    Crow, Lauren
    Geoerger, Birgit
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] EFFICACY AND SAFETY OF ERDAFITINIB IN PATIENTS WITH HIGH-GRADE AND LOW-GRADE GLIOMAS AND PRESPECIFIED FIBROBLAST GROWTH FACTOR RECEPTOR ALTERATIONS (FGFRALT) IN THE RAGNAR TRIAL
    Reardon, David
    Welsh, Liam
    Shih, Kent
    Shimizu, Toshio
    Goeminne, Jean-Charles
    Geoerger, Birgit
    Baldini, Capucine
    Massard, Christophe
    Loriot, Yohann
    Pant, Shubham
    Sait, Sameer Farouk
    Sait, Farouk
    Thomas, Shibu
    Hammond, Constance
    Najmi, Saltant
    Triantos, Spyros
    Crow, Lauren
    Sweiti, Hussein
    Witt, Olaf
    NEURO-ONCOLOGY, 2023, 25
  • [4] Entity-independent Safety and Efficacy of Erdafitinib in Patients with advanced solid Tumors with pre-specified genomic Aberrations of FGFR (RAGNAR Interim Analysis)
    Schuler, M.
    Loriot, Y.
    Iyer, G.
    Witt, O.
    Doi, T.
    Qin, S.
    Tabernero, J.
    Reardon, D. A.
    Massard, C.
    Palmer, D. H.
    Lugowska, I.
    Coward, J.
    Corassa, M.
    Stuyckens, K.
    Liao, H.
    Najmi, S.
    Hammond, C.
    Santiago-Walker, A. E.
    Sweiti, H.
    Pant, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 27 - 28
  • [5] Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies.
    Pant, Shubham
    Park, Joon Oh
    Su, Wu-Chou
    Schuler, Martin H.
    Loriot, Yohann
    Iyer, Gopa
    Doi, Toshihiko
    Qin, Shukui
    Tabernero, Josep
    Prenen, Hans
    Folprecht, Gunnar
    Winter, Helen
    Dal Molin, Graziela Zibetti
    Sweiti, Hussein
    Najmi, Saltanat
    Hammond, Constance
    Liao, Huimin
    Thomas, Shibu
    Triantos, Spyros
    Feng, Yin-Hsun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Erdafitinib (erda) vs chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select FGFR alterations (FGFRalt): Subgroups from the phase III THOR study
    Loriot, Y.
    Matsubara, N.
    Huddart, R. A.
    Houede, N.
    Laguerre, B.
    Guadalupi, V.
    Ku, J. H.
    Triantos, S.
    Akapame, S.
    Deprince, K.
    Mukhopadhyay, S.
    Siefker-Radtke, A. O.
    ANNALS OF ONCOLOGY, 2023, 34 : S1201 - S1201
  • [7] FGFR3 alterations (FGFRalt) in patients (pts) who develop locally advanced or metastatic urothelial cancer (mUC), and their association with tumor subtype and clinical outcomes in pts treated with erdafitinib (erda) vs. pembrolizumab (pembro)
    Siefker-Radtke, Arlene O.
    Loriot, Yohann
    Matsubara, Nobuaki
    Park, Se Hoon
    Huddart, Robert A.
    Burgess, Earle F.
    Zhang, Jiarui
    Beeharry, Neil
    Thomas, Shibu
    Stone, Nicole L.
    Deprince, Kris
    Triantos, Spyros
    Choi, Woonyoung
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).
    Siefker-Radtke, Arlene O.
    Necchi, Andrea
    Park, Se Hoon
    GarcAa-Donas, JesAs
    Huddart, Robert A.
    Burgess, Earle Frederick
    Fleming, Mark T.
    Rezazadeh, Arash
    Mellado, Begona
    Varlamov, Sergei
    Joshi, Monika
    Duran, Ignacio
    Tagawa, Scott T.
    OHagan, Anne
    Avadhani, Anjali Narayan
    Zhong, Bob
    De Porre, Peter
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Erdafitinib in pediatric patients with advanced solid tumors with fibroblast growth factor receptor (FGFR) gene alterations: RAGNAR study pediatric cohort.
    Witt, Olaf
    Geoerger, Birgit
    Dirksen, Uta
    Sait, Sameer Farouk
    Reardon, David A.
    Shih, Kent C.
    Diez, Blanca D.
    Caran, Eliana Maria Monteiro
    Karakawa, Shuhei
    Stuyckens, Kim
    Liao, Huimin
    Najmi, Saltanat
    Hammond, Constance
    Santiago-Walker, Ademi E.
    Sweiti, Hussein
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
    Pant, Shubham
    Schuler, Martin
    Iyer, Gopa
    Witt, Olaf
    Doi, Toshihiko
    Qin, Shukui
    Tabernero, Josep
    Reardon, Davida A.
    Massard, Christophe
    Minchom, Anna
    Lugowska, Iwona
    Carranza, Omar
    Arnold, Dirk
    Gutierrez, Martin
    Winter, Helen
    Stuyckens, Kim
    Crow, Lauren
    Najmi, Saltanat
    Hammond, Constance
    Thomas, Shibu
    Santiago-Walker, Ademi
    Triantos, Spyros
    Sweiti, Hussein
    Loriot, Yohann
    LANCET ONCOLOGY, 2023, 24 (08): : 925 - 935
12345